Roche Holding AG

Roche is a research-based healthcare company with two divisions: Pharmaceuticals and Diagnostics. Pharmaceuticals include Roche Pharmaceuticals and Chugai, while Diagnostics comprises Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics. Roche develops medicines for oncology, immunology, infectious diseases, ophthalmology, and neuroscience, and offers products for researchers in cell analysis, gene expression, genome sequencing, and nucleic acid purification.

FDA approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection, covering NSCLC, SCLC, melanoma, and HCC. Based on IMscin001 study, subcutaneous administration showed comparable pharmacokinetics, safety, and efficacy to intravenous. Patients preferred subcutaneous due to increased comfort and reduced clinic time.

Fulcrum Therapeutics' stock dropped >60% after its Phase 3 REACH trial for losmapimod, a potential FSHD treatment, missed its primary endpoint, leading to the suspension of the program.

Roche Holding AG remains unconcerned about side effects in a small study of its weight-loss shot CT-388, despite shares tumbling due to early release of side effect details. The company emphasizes no patients stopped treatment in the trial, and its other weight-loss candidate, CT-966, could be 'best in class.' Roche is focusing on five core therapy areas and diversifying in oncology, actively seeking partners in promising fields like antibody-drug conjugates.

Chugai Pharmaceutical filed for an additional indication with MHLW for Vabysmo, targeting angioid streaks with neovascularization, receiving orphan drug designation. Based on a Japanese phase III study, Vabysmo demonstrated vision improvement, aiming to provide a new treatment option for this rare disease.

The oral thin films market is projected to reach $7.65 billion by 2028 with a CAGR of 13.6%, driven by specialty pharmaceuticals, precision medicine, and telemedicine. Key players include ZIM Laboratories, NAL Pharma, and Cure Pharmaceutical. The market is segmented by type, disease indication, and distribution channel.